Effect of Amprya (Fampridine-PR (prolonged released 4-aminopyridine)) on the manual functions of patients with MS: STUDY
Effect of Ampyra (Fampridine-PR / prolonged released 4-aminopyridine) on the manual functions of patients with MS: STUDY
Withdrawal/reinitiation study expands on known walking speed benefits of approved MS therapy
In a new study, researchers evaluated the effect of dalfampridine treatment in people with multiple sclerosis (MS) and observed significant improvements in not only walking speed and distance, but also in gait and balance. The paper, titled “Dalfampridine Effects Beyond Walking Speed in Multiple Sclerosis,” was published in the International Journal of MS Care.